As last year, we will be very happy to attend Drug Discovery 2017 event in Liverpool (Innovation Zone, IZ1 booth). We will present our activities, the new assays that we have developed recently and our brand new robotic platform.

“Drug Discovery is ELRIG’s flagship event. Now in its 11th year, we return to ACC in Liverpool to bring together the leading lights in drug discovery research across pharma, biotech, academia and the vendor community.”

As you can see on the dedicated webpage, the event program is highly interesting:

  • Advances in Imaging
  • Drug Discovery in the 4th Dimension
  • Innovations in Assay Design, Development and Screening

And of course, don’t forget the amazing “Innovation Zone”, the right place to discover future partners, as HCS Pharma !

Come and join us in Drug Discovery 2017 in the Innovation Zone at booth IZ1, to discuss with Nathalie, our CEO and Pierre-Jean, our in vitro toxicology expert !

Nathalie will be present tuesday 3 October, 3-4 pm, on booth of our partner Molecular Devices (#D18) to answer your high-content screening (HCS) questions.  Book a time slot to meet Nathalie !

It’s a great news for Brittany biotechnologies domain. Biotrial opens a new site in USA to grow up its capacity for phase 1 studies. The Newark site will perform up to 50 studies per year ! Congratulation Biotrial.

According to Francois Peaucelle, General Manager, Biotrial, the company has started activities with studies for European and American biotech, the pharma industry, and US generics companies.

Source: Biotrial: transparency key as CRO moves forward in US

In this presentation, Dr. Kamyar Hadian (head of the and Screening Platform’ at the HelmholtzZentrum München in Munich/Germany) talk about use in – and microtissue-based assays.

has highly emerged in the past years. Especially High-Content Screening (HCS) has gained strong acceptance in the field of target validation and compounds screening as a method to follow more innovative and sophisticated assays …

%d bloggers like this: